To further estimate the strength of DP CD8+ T cells in predicting pancreatic cancer patient survival, we combined the presence of DP CD8+ T cells in central tissues with other clinicopathologic factors including age, sex, T, N, M stage, levels of CA19-9, and neoadjuvant chemotherapy in a multivariate Cox proportional hazards regression analysis. This evidence concerns the gene CD8A and pancreatic neoplasm.